跳到正文
原文
Nature 健康护理主题·· 2026-10-16AI 评分47

弥合差距:CKM综合征指南导向药物治疗的可及性与实施差异

Closing the gap: disparities in access to and implementation of guideline-directed medical therapy for CKM syndrome

AI 导读

Magdalena Madero在Nature Reviews Nephrology发表评论文章,指出CKM综合征指南导向药物治疗(GDMT)虽有充分循证支持但实际采用率偏低。文章认为结构性、经济性和公平性障碍需被克服,才能实现从高收入国家专科诊所到低资源地区基层医疗的GDMT有效实施。

正文
  • Comment
  • Published: 16 October 2026

Nature Reviews Nephrology (2026) Cite this article

Despite robust evidence supporting guideline-directed medical therapy (GDMT) for cardiovascular–kidney–metabolic syndrome, uptake remains low. Structural, economic and equity-related barriers must be overcome to enable effective implementation of GDMT across settings from subspecialty clinics in high-income countries to primary care settings in low-resource regions.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

27,99 € / 30 days

cancel any time

Subscription info for Chinese customers

We have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

39,95 €

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

References

  1. Rangaswami, J., Lo, K. B. & Ndumele, C. E. The therapeutic approach to cardiovascular–kidney–metabolic syndrome. Nat. Rev. Nephrol. https://doi.org/10.1038/s41581-026-01109-6 (2026).

    Article  PubMed  Google Scholar 

  2. Shin, J.-I. et al. Prescription patterns for sodium-glucose cotransporter 2 inhibitors in U.S. health systems. J. Am. Coll. Cardiol. 84, 683–693 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Kovesdy, C. P. et al. Real-world SGLT2 inhibitor (SGLT2i) use in patients with CKD in the United States [abstract]. J. Am. Soc. Nephrol. https://doi.org/10.1681/ASN.202592d27ygq (2025).

  4. Jelwan, Y. et al. Finerenone prescriptions in the United States (2021–2024) by physician specialty: analysis of use and potential in the cardiovascular-kidney-metabolic space. J. Am. Heart Assoc. 15, e046837 (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Khan, S. S. et al. Development and validation of the American Heart Association’s PREVENT equations. Circulation 149, 430–449 (2024).

    Article  PubMed  Google Scholar 

  6. Ndumele, C. E. et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation 148, 1606–1635 (2023).

    Article  PubMed  Google Scholar 

  7. Pagidipati, N. J. et al. Coordinated care to optimize cardiovascular preventive therapies in type 2 diabetes: a randomized clinical trial. JAMA 329, 1261–1270 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Zheng, J., Mednick, T., Heidenreich, P. A. & Sandhu, A. T. Pharmacist- and nurse-led medical optimization in heart failure: a systematic review and meta-analysis. J. Card. Fail. 29, 1000–1013 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Eberly, L. A. et al. Racial, ethnic, and socioeconomic inequities in glucagon-like peptide-1 receptor agonist use among patients with diabetes in the US. JAMA Health Forum 2, e214182 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  10. GBD 2023 Chronic Kidney Disease Collaborators. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. Lancet 406, 2461–2482 (2025).

    Article  Google Scholar 

  11. López, D. S., Hernández Vargas, J. A., Urina-Jassir, M., Urina-Triana, M. & Franco, O. H. Reducing the gap of chronic kidney disease in low- and middle-income countries: what is missing? Lancet Reg. Health Am. 28, 100625 (2023).

    PubMed  PubMed Central  Google Scholar 

  12. Bello, A. K. et al. An update on the global disparities in kidney disease burden and care across world countries and regions. Lancet Glob. Health 12, e382–e395 (2024).

    CAS  Google Scholar 

  13. World Health Organization. The Selection and Use of Essential Medicines 2021: Report of the 23rd WHO Expert Committee on the Selection and Use of Essential Medicines (WHO Technical Report Series No. 1035) (WHO, 2021).

  14. Global Health & Population Project on Access to Care for Cardiometabolic Diseases (HPACC). Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis. Lancet Diabetes Endocrinol. 9, 825–836 (2021).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico

    Magdalena Madero

Authors

  1. Magdalena Madero

Corresponding author

Correspondence to Magdalena Madero.

Ethics declarations

Competing interests

M.M. has consulted for AstraZeneca, Bayer, and Boehringer Ingelheim, provided expert testimonies for AstraZeneca, Bayer, and Boehringer Ingelheim and received grant funding or has pending grants from AstraZeneca, Bayer, Boehringer and the Renal Research Institute. She has also received travel support from AstraZeneca.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Madero, M. Closing the gap: disparities in access to and implementation of guideline-directed medical therapy for CKM syndrome. Nat Rev Nephrol (2026). https://doi.org/10.1038/s41581-026-01136-3

Download citation

  • Published: 16 October 2026

  • Version of record: 16 October 2026

  • DOI: https://doi.org/10.1038/s41581-026-01136-3

来源:Nature 健康护理主题 · nature.com